Registration
SIDLEY AUSTIN LLP for INTERCEPT PHARMACEUTICALS, INC.
Firm
Income
—
Expenses
—
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
FDAs regulation of rare disease drugs
| Lobbyist | Covered position, as disclosed |
|---|---|
| MICHAEL E BORDEN New | Senior Counsel, House Financial Services Committee; Counsel, House Financial Services Committee; Legislative Assistant, Office of Rep. Jim Leach |
| PATRICIA LOUISE DELOATCHE New | Health Policy Director, Sen. Orrin Hatch; Chief of Staff, Legislative Director, Legislative Assistant, Rep. Mike Bilirakis |
Foreign entities
Foreign owners and affiliates the filer disclosed. Amounts are as declared on this filing.
| Entity | Country | Principal place of business | Ownership | Contribution declared |
|---|---|---|---|---|
| ALFASIGMA S.P.A. | Italy | Italy | 100.0% | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.